Formulation and Pharmacokinetics of Self-Assembled Rifampicin Nanoparticle Systems for Pulmonary Delivery

[1]  G. Hochhaus,et al.  Slow Release Formulations of Inhaled Rifampin , 2008, The AAPS Journal.

[2]  A. Hickey,et al.  Preparation and in Vivo Evaluation of a Dry Powder for Inhalation of Capreomycin , 2008, Pharmaceutical Research.

[3]  B. Pulliam,et al.  Nanoparticles for drug delivery to the lungs. , 2007, Trends in biotechnology.

[4]  R. Tan,et al.  Drug release study of large hollow nanoparticulate aggregates carrier particles for pulmonary delivery. , 2007, International journal of pharmaceutics.

[5]  M. Rad-Malekshahi,et al.  Preparation and antibacterial activity evaluation of rifampicin-loaded poly lactide-co-glycolide nanoparticles. , 2007, Nanomedicine : nanotechnology, biology, and medicine.

[6]  A. Hickey,et al.  Inhaled Large Porous Particles of Capreomycin for Treatment of Tuberculosis in a Guinea Pig Model , 2007, Antimicrobial Agents and Chemotherapy.

[7]  Manmohan J. Singh,et al.  A practical approach to the use of nanoparticles for vaccine delivery. , 2006, Journal of pharmaceutical sciences.

[8]  A. Hickey,et al.  Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres in the treatment of tuberculosis in the guinea pig. , 2006, The Journal of antimicrobial chemotherapy.

[9]  R. Löbenberg,et al.  Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles. , 2006, International journal of pharmaceutics.

[10]  W. Seeger,et al.  Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. , 2006, Toxicology and applied pharmacology.

[11]  K. Johnston,et al.  Single dose and multiple dose studies of itraconazole nanoparticles. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[12]  D. Stallknecht.  FACT SHEET , 2006 .

[13]  K. Kisich,et al.  The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. , 2005, American Journal of Respiratory and Critical Care Medicine.

[14]  Sadhna Sharma,et al.  Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. , 2005, International journal of antimicrobial agents.

[15]  N. Chew,et al.  Effect of amino acids on the dispersion of disodium cromoglycate powders. , 2005, Journal of pharmaceutical sciences.

[16]  C. Remuñán-López,et al.  Microencapsulated chitosan nanoparticles for lung protein delivery. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[17]  J. Birchall,et al.  The use of amino acids to enhance the aerosolisation of spray‐dried powders for pulmonary gene therapy , 2005, The journal of gene medicine.

[18]  Shohei Sugimoto,et al.  Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[19]  Anjali Sharma,et al.  Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. , 2004, The Journal of antimicrobial chemotherapy.

[20]  Rajesh Pandey,et al.  Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. , 2003, The Journal of antimicrobial chemotherapy.

[21]  W. Seeger,et al.  Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[22]  L. Brannon-Peppas,et al.  Molecular weight distribution changes during degradation and release of PLGA nanoparticles containing epirubicin HCl , 2003, Journal of biomaterials science. Polymer edition.

[23]  Cassie Thomas.  A literature review of the problems of delayed presentation for treatment and non-completion of treatment for tuberculosis in less developed countries and ways of addressing these problems using particular implementations of the DOTS strategy. , 2002, Journal of management in medicine.

[24]  D A Weitz,et al.  Trojan particles: Large porous carriers of nanoparticles for drug delivery , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[25]  A. Lowman,et al.  Biodegradable nanoparticles for drug delivery and targeting , 2002 .

[26]  A. Hickey,et al.  Pharmacokinetics of aerosolized rifampicin in the guinea pig , 2001 .

[27]  C. Newcomer,et al.  Airways delivery of rifampicin microparticles for the treatment of tuberculosis. , 2001, The Journal of antimicrobial chemotherapy.

[28]  C. Newcomer,et al.  Respirable PLGA Microspheres Containing Rifampicin for the Treatment of Tuberculosis: Screening in An Infectious Disease Model , 2001, Pharmaceutical Research.

[29]  David G. Russell,et al.  Mycobacterium tuberculosis: here today, and here tomorrow , 2001, Nature Reviews Molecular Cell Biology.

[30]  M. R. Aberturas,et al.  Freeze-drying of polycaprolactone and poly(D,L-lactic-glycolic) nanoparticles induce minor particle size changes affecting the oral pharmacokinetics of loaded drugs. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[31]  Anthony J. Hickey,et al.  Respirable PLGA Microspheres Containing Rifampicin for the Treatment of Tuberculosis: Manufacture and Characterization , 2000, Pharmaceutical Research.

[32]  H. Frijlink,et al.  A review of the technical aspects of drug nebulization , 2000, Pharmacy World & Science.

[33]  L. Brannon-Peppas,et al.  Optimization of Preparation Techniques for Poly(Lactic Acid-Co-Glycolic Acid) Nanoparticles , 2000 .

[34]  H. Takeuchi,et al.  Pulmonary delivery of insulin with nebulized DL-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[35]  D. Mitchison,et al.  Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications. , 1999, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[36]  N Lotan,et al.  Large porous particles for pulmonary drug delivery. , 1997, Science.

[37]  J. Patton,et al.  Mechanisms of macromolecule absorption by the lungs , 1996 .

[38]  P. Byron.  Respiratory Drug Delivery , 1989 .

[39]  D. Mitchison,et al.  Suitability of rifampicin for intermittent administration in the treatment of tuberculosis. , 1970, Tubercle.

[40]  R. Riley,et al.  Aerial dissemination of pulmonary tuberculosis. A two-year study of contagion in a tuberculosis ward. 1959. , 1959, American journal of epidemiology.

[41]  J. Patton,et al.  The lungs as a portal of entry for systemic drug delivery. , 2004, Proceedings of the American Thoracic Society.

[42]  Daniel Yamins,et al.  Direct lung delivery of para-aminosalicylic acid by aerosol particles. , 2003, Tuberculosis.

[43]  R. Namdar,et al.  Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. , 1999, Chest.

[44]  J. Heyder,et al.  Deposition of particles in the human respiratory tract in the size range 0.005–15 μm , 1986 .

[45]  J. Heyder,et al.  Mathematical models of particle deposition in the human respiratory tract , 1984 .

[46]  J. Pritchard,et al.  Determination of poly(vinyl alcohol) via its complex with boric acid and iodine , 1979 .